Table 2.
High-resolution trans-thoracic echocardiography performed on conscious MuRF1Tg+ and age-matched wild-type mice at baseline, 1 week, and 2 weeks after daily i.p. T3 treatment. Data represent means ± S.E.M. Groups were first analyzed with a one-way ANOVA, and if significant, analyzed with a Holm–Sidak test for pairwise comparisons.
| MuRF1Tg+ Wild type Baseline n = 16 | MuRF1Tg+ Baseline n = 11 | MuRF1Tg+ wild type Thyroid hormone 1 week n = 16 | MuRF1Tg+ Thyroid hormone 1 week n = 10 | MuRF1Tg+ wild type Thyroid hormone 2 weeks n = 16 | MuRF1Tg+ Thyroid hormone 2 weeks n = 11 | |
|---|---|---|---|---|---|---|
| PWTD (mm) | 1.02 ± 0.02 | 0.96 ± 0.02 | 3.15 ± 0.10 | 3.27 ± 0.11 | 3.20 ± 0.11 | 3.54 ± 0.13 |
| AWTS (mm) | 1.70 ± 0.05 | 1.54 ± 0.06 | 1.48 ± 0.07§,§,** | 1.80 ± 0.09*** | 1.64 ± 0.10§,* | 2.23 ± 0.14 |
| LVESD (mm) | 1.53 ± 0.07 | 1.88 ± 0.14 | 1.36 ± 0.06 | 1.18 ± 0.12 | 1.41 ± 0.04 | 1.11 ± 0.03* |
| PWTS (mm) | 1.58 ± 0.04 | 1.33 ± 0.06 | 1.86 ± 0.05§ | 1.60 ± 0.03 | 1.92 ± 0.05§,§§,* | 1.50 ± 0.06 |
| LV Vol; d (L) | 37.4 ± 2.4 | 41.6 ± 4.6 | 40.3 ± 3.0 | 44.1 ± 3.7 | 42.1 ± 3.3 | 53.4 ± 4.6 |
| LV Vol; s (L) | 6.8 ± 0.8 | 12.0 ± 2.1 | 6.3 ± 0.9 | 10.4 ± 1.1 | 8.5 ± 1.4 | 17.9 ± 2.4†,§,§§ |
| LV mass (mg) | 116.6 ± 7.3 | 107.4 ± 9.3 | 178.5 ± 8.3 | 137.7 ± 7.4 | 201.8 ± 110.8§,§§,** | 155.0 ± 10.2 |
| LV mass/BW (mg/g) | 4.1 ± 0.3 | 5.1 ± 0.7 | 6.2 ± 0.2§ | 5.2 ± 0.3 | 6.7 ± 0.2§,§§,** | 5.5 ± 0.3 |
| BW (g) | 29.3 ± 1.3 | 27.7 ± 1.8 | 29.9 ± 1.1 | 26.9 ± 1.5 | 29.8 ± 0.9 | 28.1 ± 1.1 |
| HR (bpm) | 711 ± 13§§ | 679 ± 10§§ | 802 ± 9 | 802 ± 7 | 798 ± 13 | 768 ± 6§ |
P < 0.001 vs all other wild-type groups.
P < 0.001 vs matched wild type.
P < 0.001 vs MuRF1Tg+ 2 weeks after T3 treatment.
P < 0.001 vs MuRF1Tg+ baseline.
P < 0.001 vs baseline groups
P < 0.001 vs 1 week T3 groups. HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole; PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, calculated as (LVEDD–LVESD)/LVEDD ×100; EF%, ejection fraction calculated as (end Simpson’s diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume ×100, ND, not determined